Featured Stories
New Active Substance First Launches Rebound In 2017
2017 was the second-best year for new drug launches worldwide since the start of the millennium, new research by Informa Pharma Intelligence's Pharmaprojects has found.
Pharma Q1 Results Preview: Lilly, Biogen, Amgen, GSK & Roche
Investors await news from Lilly on whether it will use repatriated cash for M&A; from Biogen on its Spinraza and gene therapy strategies in light of Novartis' AveXis deal; and from Amgen on pipeline programs and acquisitions as major products face new competition. Immuno-oncology combination updates are anticipated from Roche, plus guidance on how GSK will cope with Advair generics, HIV competition from Gilead and the cost of new drug launches is expected.
Next-Generation CAR-Ts Tackle First-Generation Safety, Solid Tumor Challenges
New strategies to overcome safety, solid tumor and other challenges associated with CAR-T therapies – and some early clinical data for patients treated with Poseida's, Celyad's and Autolus' novel products – were featured at the American Association for Cancer Research (AACR) meeting.
Latest News
Recent Tweets from Scrip
Meeting Growth Challenges Roundtable Panel Part 3: Pursuing Growth Without Overreaching
Three decades ago when biotech was in its infancy many of the pioneers had ambitions to create fully integrated pharmaceutical companies (FIPCOs). Picking low hanging fruit – recombinant versions of therapeutically relevant human proteins, such as insulin, human growth hormone, erythropoietin and tissue plasminogen activator – a number of the first movers prospered but many withered on the vine. The FIPCO model fell out of fashion and subsequent start-ups pursued strategies that took assets to proof of concept before licensing to established commercial organizations. The advent of personalized medicines and initiatives to incentivize development of therapeutics to treat orphan diseases has underpinned a renaissance of the FIPCO model. However, challenges still exist.
Commercial Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Biogen Re-Ups With Ionis In Search Of A Neuroscience 'Innovation Engine'
Merck KgaA-P&G Deal: Complex In Some Emerging Markets But No ‘Dis-Synergies’
Merck KGaA’s sale of its global consumer health business to Procter & Gamble (P&G) is expected to be a somewhat complex affair in emerging markets like India, where it has a listed entity and a seemingly cohesive consumer health and pharma footprint, though Merck's management emphasized that no “dis-syneries” are anticipated.
Sweet Enough? Takeda Raises, Adds Cash To Shire Offer
Takeda has further bumped up its offer for acquisition target Shire, raising the per share price and cash component, in what the Japanese firm says is a “compelling” proposal worth well over $60bn. Will it be fourth time lucky?
STORM CEO Outlines Business Model And Pipeline Goals
Keith Blundy, CEO of STORM Therapeutics, discusses the company’s founding and upcoming milestones.
Shire Rejects Multiple Equity-Loaded Takeda Offers, Allergan Declines To Bid
Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows
A new US drug spending report from IQVIA parses out how rebates impact drug spending and explores affordability for patients. The data show drug makers offset about 28% of drug spending and provide some support to industry's arguments on drug pricing.
US Generic Drug Spending Declines In A New Development – IQVIA Report
Generic drug spending declined in the US by $5.5bn in 2017 after growing in 2013-2016, pointing to the challenging generic drug dynamics in the US. Volume share data on marketed biosimilars shows impact of insurer control.
Novartis Allays Concerns Over Cosentyx Sales Miss
The Swiss major has calmed investor fears over the growth trajectory of Cosentyx, maintaining that its move into first-line therapy in ankylosing spondylitis and psoriatic arthritis, as well as psoriasis, will continue to drive sales.
Policy & Regulation Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Approval Of GW Pharma's Cannabidiol Epidiolex 'No Longer A Pipe Dream'
Set to be the first FDA-approved cannabidiol-based drug, Epidiolex would treat seizures associated with the rare childhood epilepsy indications Lennox-Gastaut syndrome and Dravet syndrome.
China Vs Cancer: An Infographic Snapshot
Cancer cases are rising in China, with larger increases for certain types including thyroid and pancreatic. To combat the rising tide, the government will implement zero tariffs on imported anticancer drugs from May.
Modus CEO Says Rare Disease Priority Review Voucher To Be Key Catalyst
The US FDA gives Sweden's privately held Modus Therapeutics rare pediatric disease designation for sickle cell disease.
India Leads Global 65% Surge In Antibiotics Use
Human antibiotic consumption globally jumped dramatically between 2000 and 2015, with India posting the biggest rise, reports a new US study, which calls for a radical policy rethink to prevent antimicrobial drug resistance soaring.
Research & Development Explore this Topic
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pipeline Watch: Phase III Updates For Eravacycline, Opdivo And Keytruda
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
Gilead presented early data for combinations of its three mechanisms in NASH, but analysts noted the findings may undercut its lead candidate selonsertib. Plus EASL takeaways for Genfit, NGM and Madrigal.
Publisher's Spotlight: The 2018 Scrip Awards Is Now Open For Entries
Come and celebrate your vital contribution to improving human health worldwide – the 2018 Scrip Awards is now open for entries.
Experts Challenge GSK Triple Inhaled COPD Therapy Claims
While GSK and collaborators publish findings from the IMPACT trial comparing once-daily single-inhaler triple versus dual therapy in patients with COPD in NEJM, two clinicians in an accompanying editorial argue that the trial falls short of providing robust evidence for switching strategy.
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.